Engineered Immune Effector Cell with CD16 Protein for Shear Resistance
Summary
USPTO published patent application US20260108605A1, filed September 27, 2023, covering a genetically modified immune effector cell expressing a recombinant human CD16 protein engineered with amino acid additions, deletions, and replacements that confer enhanced shear resistance. The application names five inventors: Fuwei JIANG, Tingting LIU, Yifang WANG, Cuiqing YANG, and Zhuoxiao CAO. CPC classifications span immunology (A61K 38/1774, A61K 39/39558), oncology (A61P 35/00), and protein engineering (C07K 14/7051, C07K 16/2803).
“The present application relates to a genetically modified immune cell for expressing a recombinant human CD16 protein.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108605A1 for an engineered immune effector cell expressing a recombinant human CD16 protein with enhanced shear resistance. The CD16 protein is modified through additions, deletions, and replacements of one or more amino acids relative to the wild-type sequence. The application is classified under A61P 35/00 (antineoplastic agents) and C07K 16/2803 (CD16 antibodies).
Pharmaceutical and biotechnology companies developing cell-based immunotherapies, particularly those working with antibody-dependent cellular cytotoxicity (ADCC) mechanisms involving CD16, should monitor this application's prosecution. The shear-resistance modification may signal advances in the mechanical durability of engineered immune cells for therapeutic deployment.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ENGINEERED IMMUNE EFFECTOR CELL AND COMPOSITION AND USE THEREOF
Application US20260108605A1 Kind: A1 Apr 23, 2026
Inventors
Fuwei JIANG, Tingting LIU, Yifang WANG, Cuiqing YANG, Zhuoxiao CAO
Abstract
The present application relates to a genetically modified immune cell for expressing a recombinant human CD16 protein. The recombinant human CD16 protein has additions, deletions and replacements of, or any combination of the additions, deletions and replacements of one or more amino acids as compared to a wild-type amino acid sequence, and has enhanced shear resistance.
CPC Classifications
A61K 40/15 A61K 38/1774 A61K 39/39558 A61K 40/31 A61K 40/4211 A61P 35/00 C07K 14/7051 C07K 14/70535 C07K 16/2803 C07K 2319/00
Filing Date
2023-09-27
Application No.
19116575
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.